| Oct 15 |
Exelixis and MSD to trial cancer therapies together in clinical collaboration
|
| Oct 14 |
Exelixis & Merck sign development collaboration for head, neck cancer treatment and renal cell carcinoma
|
| Oct 14 |
Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma
|
| Oct 9 |
ONCOLOGY COMMERCIALIZATION LEADER P.J. HALEY TO JOIN NETRAMARK BOARD OF DIRECTORS
|
| Oct 7 |
Exelixis Gains 20.7% in Three Months: Is This the Right Time to Buy?
|
| Oct 7 |
Exelixis Gains 20.7% in Three Months: Is This the Right Time to Buy?
|
| Oct 2 |
EXEL vs. CSLLY: Which Stock Is the Better Value Option?
|
| Sep 26 |
2 Growth Stocks to Buy With Less Than $100
|
| Sep 24 |
Exelixis, Inc.'s (NASDAQ:EXEL) institutional investors lost 4.0% over the past week but have profited from longer-term gains
|
| Sep 20 |
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
|
